Kenvue Inc. has unveiled findings from recent clinical studies focused on oral health and skin care. In the realm of oral health, 12 new studies were shared, including the first clinical trial assessing the safety and effectiveness of LISTERINE® mouth rinse in individuals with type 1 and type 2 diabetes. The results demonstrated that both alcohol-containing and alcohol-free LISTERINE® mouthwash significantly reduced plaque and gingivitis in these patients compared to control groups. Additionally, another study indicated that LISTERINE® mouthwash effectively reduced plaque and gingivitis in adults aged 55 and older after one week of use. In the domain of skin care, Kenvue conducted 14 clinical studies under its Skin Health & Beauty brands such as Neutrogena® and Aveeno®. These studies concentrated on skin barrier health through hydration, longevity-supporting technologies, and sun protection. The findings from these studies have already been presented, showcasing Kenvue's commitment to advancing healthcare solutions through scientific research.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.